The outbreak of Shiga-toxin-producing Escherichia coli (STEC) O104:H4 in Northern Germany resulted in 53 deaths among nearly 3,000 STEC cases and over 800 confirmed HUS cases from May 22 to July 27.
A study analyzed the effectiveness of different treatments for HUS in 631 patients across hospitals in Germany, Sweden, and the Netherlands, focusing on best supportive care (BSC), therapeutic plasma exchange (TPE), and TPE with eculizumab (TPE-Ecu).
Findings indicated that while BSC had the best outcomes regarding creatinine levels and fewer neurological symptoms, the overall short-term outcomes were surprisingly better than expected despite severe complications in patients.
Objective: To evaluate the effect of different treatment strategies on enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome.